You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Alzheimer's Disease Therapeutic

    SBC: APHIOS CORPORATION            Topic: NIA

    DESCRIPTION (provided by applicant): Alzheimer's Disease (AD) is a significant neurological disorder that afflicts more than 4.5 million Americans and more than 10 million people worldwide. The lack of a cure for AD will result in a demand for better and safer AD drugs. All of the drugs on the market today have serious side effects. Recently, researchers at The Blanchette Rockefeller Neurosci ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  2. Type III Secretion Inhibitors for Anti-Infective Therapy

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Pseudomonas aeruginosa infection is the leading cause of hospital-acquired pneumonia in patients undergoing mechanical ventilation. Current antibiotic treatments exhibit failure rates as high as 18%, even when the organism is susceptible to the antibiotic being administered. The goal of this project is to address this critical medical need by identifying specif ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Diagnostic Sequencing System for HIV Resistance Testing

    SBC: INTELLIGENT BIO-SYSTEMS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): As of 2008 the CDC estimated that there were approximately 1.1 million persons in the U.S. infected with HIV- 1 and about 56,000 new cases are diagnosed each year. During the mid-to-late 1990s, advances in treatment slowed the progression of HIV to AIDS and related deaths. Unfortunately, the treatment often leads to the emergence of drug resistant mutants of HI ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  4. Rapid sensitive low-cost test for resistant microbes causing hospital infections

    SBC: FIRST LIGHT BIOSCIENCES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): We propose to develop a novel automated platform to enable rapid, sensitive, user-friendly, and cost-effective screening for the antibiotic resistant bacteria that frequently cause serious healthcare associated infections. Every year, about 100,000 deaths result from 2 million serious healthcare associated infections at an estimated cost of 35B. About 20,000 f ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  5. Confirmatory Immunoblot Test for Chagas' Disease

    SBC: IMMUNETICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Chagas' Disease is a vector-borne parasitic infection of humans with Trypanosoma cruzi, which has recently been identified as an emerging and significant threat to transfusion safety and the blood supply. It is a chronic and potentially fatal condition which affects over 10 million people living in tropical regions of the Americas, is endemic in 21 countri ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  6. Agonists of the RIG-I Innate Immune Pathway

    SBC: KINETA, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Through Phase I studies, we have identified five lead small molecule compounds with drug-like properties that activate innate immune response pathways and inhibit the replication of RNA viruses such as hepatitis C virus (HCV), influenza virus (FLU), and West Nile virus (WNV). There is a tremendous commercial demand for new antiviral products with novel mechan ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  7. Protective vaccine for H5N1 Flu using H5 protein and a novel TLR4 agonist.

    SBC: TRIA BIOSCIENCE CORP.            Topic: NIAID

    DESCRIPTION (provided by applicant): H5N1 is a highly pathogenic avian influenza virus that can cause severe disease and death in humans. H5N1 is spreading rapidly in bird populations world-wide and there is great concern that this virus will begin to transmit between people and cause a global pandemic catastrophe. Vaccines are the cornerstone strategy for combating avian flu but there are complex ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  8. Automated Molecular Diagnostics for Rapid Detection of Dengue Viremia Using Whole

    SBC: IQUUM, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): We propose to develop a highly sensitive and rapid point-of-care nucleic acid test based on IQuum's lab-in-a-tube (Liat ) platform for the diagnosis of patients with dengue fever or dengue hemorrhagic fever from whole blood samples. The Liat Dengue Assay will utilize the Liat Analyzer to enable the minimally trained personnel to perform the dengue infectio ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  9. Prevention of Tumor Recurrence Following Surgical Resection (Phase II)

    SBC: FIFTH BASE, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): In 2009, there were 219,000 new lung cancer cases reported. Roughly one-quarter of these patients will be considered candidates for curative surgical resection, where the preservation of lung function must be balanced against the extent of tissue removed. As a result, patients requiring these limited resection procedures suffer a high risk of developing loca ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  10. Hydrogel Particle-Based microRNA Profiling for Discovery and Cancer Diagnostics

    SBC: ELUCIGEL TECHNOLOGIES            Topic: NCI

    DESCRIPTION (provided by applicant): MicroRNA targets have shown enormous potential for understanding, diagnosing, and even treating the world's most prevalent diseases including cancer, heart disease, Alzheimer's, diabetes and many more. Unfortunately, miRNAs are particularly challenging to quantify due to their small size, sequence homology, and wide range of abundance. As such, miRNA ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government